SAN FRANCISCO, February 11, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the pricing of its initial public offering of 6,350,000 shares of its common stock at an initial offering price of $16.00 per share, for total gross proceeds of $101.6 million before deducting underwriting discounts and commissions and other offering expenses. The shares of Invitae’s common stock are expected to begin trading on the New York Stock Exchange under the symbol “NVTA” on February 12, 2015. All of the shares in the offering are being offered by Invitae. The offering is expected to close on or about February 18, 2015, subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 952,500 shares of common stock at such offering price, less customary underwriting discounts and commissions.
J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Cowen and Company, LLC and Leerink Partners LLC are acting as co-managers.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on February 11, 2015. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to and describing the terms of the offering, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803‐9204. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Based in San Francisco, Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic test comprising over 200 genes for a variety of genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics.